A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice
NCT05200221
·
clinicaltrials.gov ↗
UNKNOWN
Status
300
Enrollment
OTHER
Sponsor class
Conditions
Donafenib
Hepatocellular Carcinoma
Sponsor
Shanghai Zhongshan Hospital